NADK

Across TCGA pan-cancer cohorts, NADK mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NADK data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NADK mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NADK expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where NADK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.546	0.239	.001	9	view →
LUAD	DFS	Tertile	III,IV	0.767	0.433	.017	6	view →
HNSC	OS	Median	IV	0.827	0.607	.032	2	view →
LSCC	DFS	Median	All	0.899	0.472	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NADK–PDAC (OS)

Open the PDAC breakdown →